Cancers

Journal Browser

► Journal Browser

The Evolving Role of Immunotherapy and Radiotherapy in the Non-operative Management of Esophageal and Rectal Cancer

Share This Special Issue

Special Issue Editors

Special Issue Information

Dear Colleagues,

This Special Issue welcomes original research that may be preclinical, translational, or clinical regarding radiotherapy or immunotherapy (or preferably both) in the non-operative management of rectal and esophageal cancers. Submissions may also focus on methods of disease surveillance post-therapy, molecular/clinical predictors of response, normal tissue toxicity, and novel treatment strategies to overcome therapeutic resistance. Topics including novel therapeutic agents or interventions for decreasing normal tissue toxicity of either immunotherapy or radiotherapy for esophageal or rectal cancer, as well as predictors of normal tissue toxicity, will also be acceptable. Studies examining the dose, fractionation, and timing of radiotherapy combined with immunotherapy and their differing effects on tumor cell immune evasion, the tumor microenvironment, or pro-inflammatory signaling cascades will also be welcomed. Submissions concerning novel techniques that correlate radiomics and/or pathology with clinical outcomes of radioimmunotherapy in rectal or esophageal cancer are encouraged as well.

We look forward to receiving your contributions.

Dr. Christopher L. Hallemeier
Dr. Krishan R. Jethwa
Dr. Cameron M. Callaghan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

radiotherapy
immunotherapy
non-operative management
esophageal cancer
rectal cancer

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

14 pages, 5948 KiB

Open AccessArticle

ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma

by Le Zhang, Yueyuan Zheng, Wenwen Chien, Benjamin Ziman, Sandrine Billet, H. Phillip Koeffler, De-Chen Lin and Neil A. Bhowmick

Cancers 2023, 15(22), 5377; https://doi.org/10.3390/cancers15225377 - 12 Nov 2023

Viewed by 1057

Abstract

ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8⁺ T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8⁺ T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8⁺ T cell recruitment and CD8⁺ T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC. Full article

(This article belongs to the Special Issue The Evolving Role of Immunotherapy and Radiotherapy in the Non-operative Management of Esophageal and Rectal Cancer)

► Show Figures

Figure 1

Review

Jump to: Research

12 pages, 1175 KiB

Open AccessReview

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas

by Alexander A. Dermanis, Sivesh K. Kamarajah and Benjamin Tan

Cancers 2023, 15(19), 4741; https://doi.org/10.3390/cancers15194741 - 27 Sep 2023

Viewed by 714

Abstract

Historically, oesophageal and gastro-oesophageal junction adenocarcinomas were associated with a poor prognosis. The advent of neoadjuvant therapy has transformed the management of oesophageal and gastro-oesophageal junction adenocarcinomas further and offers the possibility to reverse disease progression, eliminate micrometastasis, and offer potentially better outcomes for these patients. This review provides an overview of landmark clinical trials in this area, with different treatment regimens considered over the years as well as potential therapeutic agents on the horizon that may transform the management of oesophageal and gastro-oesophageal junction adenocarcinomas further. Full article

(This article belongs to the Special Issue The Evolving Role of Immunotherapy and Radiotherapy in the Non-operative Management of Esophageal and Rectal Cancer)

► Show Figures